The effect of topical bevacizumab on corneal neovascularization.
The effect of topical bevacizumab on corneal neovascularization.
复制标题
DOI：
10.1016/j.ophtha.2008.02.013
复制
发表时间：
2008-06-01
期刊：
影响因子：
13.7
通讯作者：
Kim, Tae-im
中科院分区：
文献类型：
--
作者：
Kim, Sang Woo;Ha, Byung Jin;Kim, Tae-im
目的：观察贝伐单抗在3个月内对角膜新生血管(NV)的影响。设计：前瞻性、非随机、隐蔽性观察病例系列。对象：7例10只眼角膜新生血管患者。眼科检查包括视力、裂隙灯检查和眼压计。主要观察指标：角膜NV和眼科检查的变化。结果：10只眼中有7只眼的角膜NV下降，通常在治疗后1个月内。10只眼中有6只眼出现上皮病(上皮缺损、上皮糜烂)，1只眼出现角膜变薄。结论：局部应用贝伐单抗能有效地降低角膜新生血管。然而，到了第二个月，出现不良反应的风险增加了。
PURPOSE: To examine the effect of topical bevacizumab on corneal neovascularization (NV) over a period of 3 months.DESIGN: Prospective, nonrandomized, masked observational case series.PARTICIPANTS: Ten eyes of 7 patients with corneal NV.METHODS: Patients received topical bevacizumab (1.25%) twice daily. Ophthalmic evaluations included visual acuity, slit-lamp examination, and tonometry.MAIN OUTCOME MEASURES: Corneal NV and changes in ophthalmic evaluations.RESULTS: Decreased corneal NV was noted in 7 of 10 eyes, usually within 1 month of treatment. Epitheliopathy (epithelial defect, epithelial erosion) was observed in 6 of 10 eyes, 1 resulting in corneal thinning. Adverse effects generally appeared during the second month of treatment.CONCLUSIONS: Topical application of bevacizumab was effective in reducing corneal NV within the first month. However, by the second month there was an increased risk of adverse effects.